Molecular genetics of the n-acetyltransferases

Pharmacogenetics

Volumn 3, Issue 1, 1993, Pages 45-50

  Grant, Denis M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE; CARCINOGEN; COMPLEMENTARY DNA; ISONIAZID; PROCAINAMIDE; SULFADIMIDINE;

ACETYLATOR PHENOTYPE; CONFERENCE PAPER; DRUG METABOLISM; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; MOLECULAR GENETICS; NONHUMAN; XENOBIOTIC METABOLISM;

ALLELES; AMINES; ANIMAL; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOGENS; HUMAN; MOLECULAR BIOLOGY; POLYMORPHISM (GENETICS); POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RABBITS;

EID: 0027476961     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199302000-00005     Document Type: Article

References (35)

1. Andres HH, Vogel RS, Tarr GE, Johnson L, Weber WW. Purification, physicochemical, and kinetic properties of liver acetyl- CoA:arylamine N-acetyltransferase from rapid acetylator liver. Mol Pharmacol 1987: 31, 446-456.
2. Blum M, Grant DM, Demierre A, Meyer UA. Nucleotide sequence of a full-length cDNA for arylamine N-acetyltransferase from rabbit liver. Nucl Acids Res 1989a: 17, 3589.
3. Blum M, Grant DM, Demierre A, Meyer UA. N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc Nat Acad Sci USA 1989b: 86, 9554-9557.
4. Blum M, Grant DM, McBride OW, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990: 9, 193-203.
5. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Nat Acad Sci USA 1991: 88, 5237-5241.
6. Bonicke R, Lisboa BP. On the inherited basis of intraindividual constancy of isoniazid elimination in man (studies of monozygotic and dizygotic twins). Naturwissenschaften 1957: 44, 314.
7. Bonicke R, Reif W. Enzymatic inactivation of isonicotinic acid hydrazide in humans and animals. Arch Exp Pathol Pharmak 1953: 220, 321-333.
8. Coroneos E, Hickman D, Risch A, Kelly SL, Sim E. Arylamine N-acetyltransferase in cultured cell lines. J Basic Clin Physiol Pharmacol 1992: 3 (Suppl), 228.
9. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Therap 1991: 259, 1241-1246.
10. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyl- transferase in human liver. J Biol Chem 1990: 265, 12757-12760.
11. Dupret J-M, Grant DM. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in E. coli: evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 1992a: 267, 7381-7385.
12. Dupret J-M, Grant DM. Investigation of structure-function relationships of human arylamine N-acetyltransferases NAT1 and NAT2 by functional expression of NAT1/NAT2 protein chimeras in E. coli. J Basic Clin Physiol Pharmacol 1992b: 3 (Suppl), 193.
13. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferase. Biochem Biophys Res Comm 1991: 177, 1252-1257.
14. Einisto P, Watanabe M, Ishidate M, Nohmi T. Mutagenicity of 30 chemicals in Salmonella typhimurium strains possessing different nitroreductase or O-acetyltransferase activities. Mutat Res 1991: 259, 95-102.
15. Evans DAP. Therapy. In: Kalow W, Goedde HW, Agarwa DP, eds. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R. Liss, Inc., 1986: 491-526
16. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989: 42, 157-234.
17. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964: 63, 394-403.
18. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960: 2, 485-491.
19. Grant DM, Lottspeich F, Meyer UA. Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett 1989: 244, 203-207.
20. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990a: 85, 968-972.
21. Grant DM, Vollmer K-O, Meyer UA. In vitro metabolism of dinaline and acetyldinaline by human liver. 12th European Workshop on Drug Metabolism, Basel, Switzerland 1990b: 147.
22. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991: 39, 184-191.
23. Grant DM, Josephy PD, Lord HL, Morrison LD. Salmonella typhim - urium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res 1992a: 52, 3961-3964.
24. Grant DM, Vohra P, Avis Y, Ima A. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 1992b: 3 (Suppl), 244.
25. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991: 4, 391-407.
26. Hein DW, Rustan TD, Grant DM. Human liver polymorphic (NAT2) and monomorphic (NAT1) N-acetyltransferase isozymes catalyze metabolic activation of N-hydroxyarylamine and N-hydroxy-N-acetyl-arylamine proximate carcinogens. PASEB J 1992: 6, A1274.
27. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991: 42, 1007-1014.
28. Mattano SS, Land S, King CM, Weber WW. Purification and biochemical characterization of hepatic arylamine N-acetyl- tansferase from rapid and slow acetylator mice: identity with arylhydroxamic acid N.O-acetyltransferase and N-hydroxy- arylamine O-acetyltransferase. Mol Pharmacol 1989: 35, 599-609.
29. Mitchell RS, Bell JC. Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis. Trans Am Clin Chem Ass 1957: 69, 98-105.
30. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990: 265, 4630-4634.
31. Patterson E, Radtke HE, Weber WW. Immunochemical studies of rabbit N-acetyltransferases. Mol Pharmacol 1980: 17, 367-373.
32. Sasaki Y, Ohsako S, Deguchi T. Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver. J Biol Chem 1991: 266, 13243-13250.
33. Trinidad A, Hein DW, Rustan TD, Ferguson RJ, Miller LS, Bucher KD, Kirlin WG, Ogolla F, Andrews AF. Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: identity with polymorphic N-hydroxyarylamine-O-acetyltransferase. Cancer Res 1990: 50, 7942-7949.
34. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Nat Acad Sci USA 1991: 88, 6333-6337.
35. Weber WW. The acetylator genes and drug response, New York: Oxford University Press, 1987.